Compare Applied Digital Corporation (APLD) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Applied Digital Corporation vs Merck & Co., Inc. — how do they compare? Applied Digital Corporation trades at $30.48 (market cap $8.90B), while Merck & Co., Inc. trades at $123.56 (market cap $305.12B). The key difference: Merck & Co., Inc. is far larger — about 34.3× Applied Digital Corporation's market cap, and Merck & Co., Inc. pays a 2.75% dividend while Applied Digital Corporation pays none. Which is the better fit depends on your goals.
| APLD | MRK | |
|---|---|---|
Market Cap | $8.90B | $305.12B |
Sector | Technology | Health |
52-Week High | $49.65 | $129.52 |
52-Week Low | $9.18 | $77.60 |
Enterprise Value | $10.00B | $348.54B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Applied Digital (APLD) trades at $31.15, down 3.53% today, amid bearish technical signals despite unanimous analyst buy ratings. The company shows strong revenue growth with $144M in 2025 and $319M projected for 2026, but remains unprofitable with negative margins. Recent news highlights APLD's pivot to AI data centers with $36B in contracted lease value, though execution risks and customer concentration persist.
Outlook: High growth potential from AI infrastructure expansion contrasts with profitability challenges and heavy capital spending. Risks include customer concentration and debt load, but analyst consensus targets $76.67 suggest significant upside if execution improves.
Merck (MRK) trades at $123.54, down 1.22% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $135.14. The company reported strong earnings beats in recent quarters, including Q1 2026, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, signaling strategic growth initiatives amid a competitive pharmaceutical landscape.
The stock presents a favorable risk-reward profile with upside potential driven by earnings momentum and strategic acquisitions, though risks include patent expirations and regulatory pressures. Institutional buying activity and a 67.57% buy rating from analysts underscore confidence, but investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applied Digital Corporation
Applied Digital provides high-performance computing (HPC) infrastructure and cloud services. It designs and operates data centers tailored for AI, machine learning, and other intensive digital workloads across North America.
Read more on APLD →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
